Table 2.
Methotrexate doses, adjunctive agents, serious toxicities, responses, and outcomes among the 20 AR-PCNSL patients who received cART plus HD-MTX. Temozolomide was administered with HD-MTX as described.21 Procarbazine and vincristine were administered with HD-MTX as described. 40 Abbreviations: Dx, diagnosis; PFS, progression-free survival; EA, etoposide plus high-dose cytarabine; R-ICE, rituximab, ifosfamide, carboplatin, etoposide; M-R, methotrexate plus rituximab; R-MBVP, rituximab, methotrexate, carmustine, etoposide, prednisone.
| Pt. | # Cycles HD-MTX |
Max Dose MTX (g/m2) |
Other Agents |
cART Regimen at Dx |
Toxicities (≥gr. 3) |
Best Response To Induction |
PFS (mo) |
2nd Line Intervention | OS (mo) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 5 | 3 | None | Etravine, Tenofovir/Emtricitabine |
None | Stable Disease |
2.9 | Lenalidomide | 24+ |
| 2 | 8 | 8 | Temozolomide Etoposide/ Ara-C (EA) |
Abacavir, darunavir/ Ritonavir |
Gr. 4 thrombocytopenia | CR | 42.9+ | 42.9+ | |
| 3 | 1 | 3 | None | Abacavir, lamuvudine, atazanavir/ritonavir | None | Not Assessed | 78+ with WBRT |
78+ | |
| 4 | 6 | 3.5 | None | Abacavir/lamuvudine, lopinavir/ ritonavir, Tenofovir, zidovudine |
None | CR | 88.4+ | 88.4+ | |
| 5 | 2 | 3 | None | Lopinavir/ritonavir, Tenofovir/ emtricitabine |
Gr. 5 sepsis (not neutropenic) |
Not Assessed | NA | 2.0 | |
| 6 | 11 | 8 | None | Lamuvudine, nevirapine, Stavudine |
None | CR | 16 | R-ICE | 24.9 |
| 7 | 8 | 8 | None | Efavirenz, Lamuvidine/Zidovudine |
None | CR | 103.5+ | 103.5+ | |
| 8 | 9 | 8 | Rituximab | Lamivudine/stavudine, Nelfinavir |
None | CR | 157.3+ | 157.3+ | |
| 9 | 5 | 3 | Rituximab | Abacavir/dolutegravir/ Lamivudine |
None | CR | 12+ | 12+ | |
| 10 | 4 | 3 | None | Abacavir/dolutegravir/ Lamivudine |
Gr. 3 neutropenia, Thrombocytopenia |
CR | 8+ | 8+ | |
| 11 | 2 | 3 | Temozolomide, Rituximab |
Lopinavir, ritonavir tenofovir/ emtricitabine | Gr. 3 febrile neutropenia Gr. 4 pancreatitis |
CR | 79+ | 79+ | |
| 12 | 6 | 3 | None | Ritonavir, atazanavir, nevirapine, Tenofovir/emtricitabine |
None | CR | 125+ | 125+ | |
| 13 | 1 | 3.5 | Procarbazine, vincristine | Raltegravir Tenofovir/emtricitabine |
Gr. 5 Sepsis (Neutropenic) |
Not Assessed | 1 | 1 | |
| 14 | 2 | 8 | None | Nevirapine/zidovudine | None | PD | 2 | WBRT | 3 |
| 15 | 2 | 8 | None | Efavirenz/emtricitabine/ Tenofovir |
None | PD | 1 | WBRT | 6 |
| 16 | 8 | 3.5 | Rituximab, procarbazine, vincristine, Ara-C | Tenofovir/emtricitabine Atazanavir |
Gr. 3 neutropenia | CR | 29+ | 29+ | |
| 17 | 7 | 3.5 | Rituximab, procarbazine, vincristine | Emtricitabine Rilpivirine/Tenofovir |
Gr. 3 Neutropenia | CR | 19+ | 19+ | |
| 18 | 7 | 3.5 | Ara-C | Efavirenz/emtricitabine Tenofovir |
Gr. 3 alt elevation | CR | 24 | M-R WBRT |
32 |
| 19 | 7 | 3.5 | Rituximab, procarbazine, vincristine, Ara-C | Efavirenz/emtricitabine Tenofovir |
Gr. 3 neutropenia, Zoster |
CR | 60+ | 60+ | |
| 20 | 8 | 8 | Rituximab, procarbazine, vincristine, Ara-C | Efavirenz/emtricitabine Tenofovir |
Gr. 3 neutropenia, Gr. 3 renal failure, Gr. 3 AST/ ALT elevation |
PR | 6 | R-MBVP WBRT |
8 |